Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

v3.22.4
Earnings (Loss) Per Common Share (Tables)
6 Months Ended
Dec. 31, 2022
Earnings (Loss) Per Common Share [Abstract]  
Schedule of Earnings (loss) Per Share, Basic and Diluted

Three Months Ended

Six Months Ended

December 31, 

December 31, 

    

2022

    

2021

2022

    

2021

Basic and diluted numerator:

Net loss attributable to iBio, Inc. from continuing operations

    

$

(10,563)

    

$

(7,191)

$

(18,100)

    

$

(12,379)

Preferred stock dividends – iBio CMO Preferred Tracking Stock

 

 

(22)

 

 

(88)

Net loss available to iBio, Inc. stockholders from continuing operations

$

(10,563)

$

(7,213)

$

(18,100)

$

(12,467)

Net loss available to iBio, Inc. stockholders from discontinued operations

$

(22,990)

$

(4,729)

$

(33,583)

$

(8,480)

Net loss available to iBio, Inc. stockholders - total

$

(33,553)

$

(11,942)

$

(51,683)

$

(20,947)

Basic and diluted denominator:

Weighted-average common shares outstanding

 

9,807

 

8,715

 

9,324

 

8,715

 

 

 

 

Per share amount - continuing operations

$

(1.08)

$

(0.83)

$

(1.94)

$

(1.43)

Per share amount - discontinued operations

$

(2.34)

$

(0.54)

$

(3.60)

$

(0.97)

Per share amount - total

$

(3.42)

$

(1.37)

$

(5.54)

$

(2.40)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

December 31, 

    

2022

    

2021

(in thousands)

Stock options

 

708

 

598

Restricted stock units

    

231

    

31

Warrants

 

7,994

 

52

Shares excluded from the calculation of diluted loss per share

 

8,933

 

681